U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C3H3BrO3
Molecular Weight 166.958
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BROMOPYRUVATE

SMILES

OC(=O)C(=O)CBr

InChI

InChIKey=PRRZDZJYSJLDBS-UHFFFAOYSA-N
InChI=1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)

HIDE SMILES / InChI

Molecular Formula C3H3BrO3
Molecular Weight 166.958
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Bromopyruvate is an halogenated analogue of pyruvic acid known as an alkylating agent reacting with thiol groups of many proteins. Bromopyruvate exerts anticancer action. It is based on the impairment of energy metabolism of tumor cells by inhibiting enzymes in the glycolysis pathway (hexokinase II, glyceraldehyde 3-phosphate dehydrogenase, phosphoglycerate kinase) and the oxidative phosphorylation (succinate dehydrogenase). Bromopyruvate induces endoplasmic reticulum stress, inhibits global protein synthesis further contributing to cancer cell death. Treatment with bromopyruvate has been administered in several cancer type models both in vitro and in vivo, either alone or in combination with other anticancer therapeutic approaches. These studies clearly demonstrate bromopyruvate broad action against multiple cancer types. This compound has also antifungal and antiparasitic activity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.67 µM [IC50]
Target ID: O00187|||Q9H498
Gene ID: 10747.0
Gene Symbol: MASP2
Target Organism: Homo sapiens (Human)
Target ID: GO:0045254 | pyruvate dehydrogenase complex
PubMed

PubMed

TitleDatePubMed
Modification of human erythrocyte pyruvate kinase by an active site-directed reagent: bromopyruvate.
2001 Nov
Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase.
2001 Nov 8
An absolute requirement of fructose 1,6-bisphosphate for the Lactobacillus casei L-lactate dehydrogenase activity induced by a single amino acid substitution.
2002 Jan
Carbonic anhydrase in mammalian vascular smooth muscle.
2004 Aug
Flux to acetate and lactate excretions in industrial fermentations: physiological and biochemical implications.
2004 Aug
Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma.
2004 Jun
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.
2004 Nov 5
Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.
2005 Jan 15
Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression.
2005 Mar
Hepatic intra-arterial injection of 3-bromopyruvate in rabbit VX2 tumor.
2006 Dec
The oncoprotein H-RasV12 increases mitochondrial metabolism.
2007 Dec 1
The cancer cell's "power plants" as promising therapeutic targets: an overview.
2007 Feb
Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: In vivo investigation in normal rabbit model.
2007 Jan
Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen.
2007 Jun
Cytometric assessment of DNA damage by exogenous and endogenous oxidants reports aging-related processes.
2007 Nov
Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization.
2008
Systems biology approach to identification of biomarkers for metastatic progression in cancer.
2008 Aug 12
Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells : ROS-mediated cell death by 3-BrPA.
2008 Dec
Revealing targeted therapy for human cancer by gene module maps.
2008 Jan 15
The role of glucose metabolism and glucose-associated signalling in cancer.
2008 Jan 18
A novel strategy involved in [corrected] anti-oxidative defense: the conversion of NADH into NADPH by a metabolic network.
2008 Jul 16
Strategies for molecular imaging dementia and neurodegenerative diseases.
2008 Jun
Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
2008 Mar 15
Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model.
2008 Nov
Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice.
2009 Apr
Hexokinase inhibitor screening based on adenosine 5'-diphosphate determination by electrophoretically mediated microanalysis.
2009 Apr
A one-pot synthesis of functionalized thiazoles from acid chlorides, secondary amines, ethyl bromopyruvate, and ammonium thiocyanate.
2009 Aug
Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.
2009 Feb
Role of the mitochondrion in programmed necrosis.
2010
3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy.
2010 Aug
3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines.
2010 Mar
Metabolic oxidative stress elicited by the copper(II) complex [Cu(isaepy)2] triggers apoptosis in SH-SY5Y cells through the induction of the AMP-activated protein kinase/p38MAPK/p53 signalling axis: evidence for a combined use with 3-bromopyruvate in neuroblastoma treatment.
2011 Aug 1
Casiopeina II-gly and bromo-pyruvate inhibition of tumor hexokinase, glycolysis, and oxidative phosphorylation.
2012 May
MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors.
2013 Jan
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:40:11 GMT 2023
Edited
by admin
on Fri Dec 15 19:40:11 GMT 2023
Record UNII
63JMV04GRK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BROMOPYRUVATE
Systematic Name English
3-Bromo-2-oxo-propionic acid
Systematic Name English
β-Bromopyruvic acid
Common Name English
3-BROMOPYRUVATE
Common Name English
NSC-11731
Code English
3-Bromopyruvic acid
Systematic Name English
NSC-62343
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 894722
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
FDA ORPHAN DRUG 390013
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
FDA ORPHAN DRUG 430514
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
FDA ORPHAN DRUG 736920
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
Code System Code Type Description
PUBCHEM
70684
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
NSC
11731
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
WIKIPEDIA
Bromopyruvate
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
MESH
C017092
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
NSC
62343
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
EPA CompTox
DTXSID7040940
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
ECHA (EC/EINECS)
214-206-5
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
SMS_ID
100000177177
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
CAS
1113-59-3
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
FDA UNII
63JMV04GRK
Created by admin on Fri Dec 15 19:40:11 GMT 2023 , Edited by admin on Fri Dec 15 19:40:11 GMT 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
Expression higher in tumor cells
Related Record Type Details
ACTIVE MOIETY